CD79A and infection: Intranasal inoculation of ChAdTS-S was used to induce rapid secretory IgA production in memory B cells by simulating the natural infection process of SARS-CoV-2 [33]; this is more likely to protect the upper respiratory tract from SARS-CoV-2 infection, resisting the virus at its point of entry [28].